bluuebunny/crossref_metadata_2025_split huggingface dataset:
Intervening factors for participation and non-participation in colorectal cancer screening in Spain.
Authors: Amador Maria Luz 
Published: June 2023

e22552 Background: The Spanish Ministry of Health introduced a population-based colorectal screening program within its common services portfolio in 2014. The program targeted adults from 50 to 69 years. They receive a personal invitation letter asking them to perform the fecal occult blood test (FOBT). To achieve public health benefits on incidence, mortality and cost-effectiveness from this screening program a 65% participation in the program is needed1.Although participation rates have been improved since 2014, there is still room from improvement as only 56% of the Spanish regions reach the participacion threshold2. In this study we examined attitudinal and social factors impacting on participation in the target population. Methods: A CAWI survey was conducted among the target population of the screening program using a nation-wide citizen panel. A representative sample of the Spanish population, with size of 5131 valid responses, was obtained. The fieldwork was conducted in June 22nd. The data was analyzed using a descriptive analysis for the entire sample as well as the logistic regression technique using the maximum likelihood estimation. This technique allows us to determine the variables that have the greatest predictive capacity with respect to the participation (or non-participation) on the (FOBT). Results: We found that 97.6% of people have heard of colon cancer, 86.8% are aware of the test, 72.5% have received the program information letter and 62.5% have performed the test (FOBT). Furthermore, logistic regression demonstrates that the reception of a program information letter (OR=7,381, p<0.01), and the prior knowledge of the screening test (FOBT) (OR=6,768, p<0,01) significantly predicted the participation. Other variables with a high contribution were age between 62-69 (OR= 1,470, p<0.01), the frequency of routine medical check-ups (OR= 1,717, p<0.01), a positive perception of routine medical checkups (OR= 1,659, p<0.01), and personal risk of colon cancer perception (OR= 1,404, p<0.01). Conclusions: The effective participation in the program is influenced by factors that are unrelated to the implementation process (including the reception of the invitation letter). Most influential factors on actual participation on the program are the prior knowledge of the program and the importance attributed to routine heath checkups. Specific interventions on these variables should be done concurrently with expanding coverage in order to achieve the goals of higher effective participation. References: 1. Segnan N, Patnick J, von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Office for Official Publications of the European Communities, 2010. 2. Molina-Barceló A, Moreno Salas J, Peiró-Pérez R, Arroyo G, Ibáñez Cabanell. REC. Desigualdades de acceso a los programas de cribado del cáncer en España y cómo reducirlas. Rev Esp Salud Pública. 2021; 95.
Real-world impact of oncology education on clinical practices at five community cancer care centers.
Authors: Johnson Elizabeth , Stefan Margaret , Theriault Nicolette , Waknine Yael , Weiss Jared 
Published: June 2023

e23003 Background: Broad based molecular testing is an underutilized but essential factor in determining patient candidacy for frontline immunotherapy (IO) for advanced NSCLC. Findings from previous educational initiatives and real-world studies such as Nadler et al. and Velcheti, et al. indicate that understanding the importance of molecular testing to optimize therapy in NSCLC, remains an educational gap among oncology clinicians. Based on this real-world data, an educational initiative was developed to impart demonstrable change in clinician’s molecular testing practices and IO treatment selection. Methods: Grand round modules held at 5 community cancer centers facilitated learners’ ability to incorporate molecular testing and treatment strategies into clinical practice, which may improve patient outcomes. Physician leaders were leveraged at each center in order to increase learner engagement, encourage peer-to-peer learning and foster a learning community and potentially encourage institutional changes. Educational impact was assessed via a matched Pre/Post Test methodology which incorporated fact based and procedural information as well as asking learners to rate their confidence and intent to perform. To evaluate educational impact, pre and post educational intervention, 100 tumor board patient cases collected by OncoLens from the five centers were analyzed to assess any change in molecular testing practices, and therapeutic selection. Results: 174 learners participated in the grand round modules, results from matched Pre- and Post-Test showed significant improvements in overall proficiency, +51% in module 1 and +89% in module 2, alongside self-reported increased intent to utilize broad-based molecular testing +93% and IO +236% in advanced NSCLC. Post-intervention tumor board cases demonstrated that effective education can lead to real-world practice changes; there was an increase (+207%) in molecular testing of NSCLC, 75% increased use of liquid biopsy, the shift towards more comprehensive testing was accompanied by more judicious determination of IO candidacy, and a 52% increase in IO implementation. Additionally, feedback from the physician leaders reported that institutional changes were implemented following the educational initiative; 3 centers now actively consider liquid biopsy if tissue quantity is not sufficient (QNS), one institution has implemented reflex testing to improve time to treatment. Conclusions: Findings suggest that onsite CME/CE targeting understanding and proficiency in molecular testing for advanced NSCLC, can translate into real-world change to clinical practice that optimizes therapeutic decision-making in patient care; community cancer center case data supports the efficacy of the education on real-world clinical practices. Nadler E, et al.doi: 10.1016/j.ctarc.2022.100522. Velcheti V, et al.doi: 10.1371/journal.pone.0206370.
Global impact of a video education platform on oncology education amongst healthcare professionals.
Authors: Leyfman Yan , Joshi Muskan , Pawar Shubhadarshini , Menon Gayathri P. , Balasubramanian Maduri , Azeez Ahmed , Wilkerson William B. , Kannan Shreevikaa , Jackewicz Sean , Zahid Emad B , Van de Kieft Alexandra , Chorya Harshal , Nadar Soumiya , Vallabhaneni Harashita , Pai Pallavi , Coloma Helena S , Wilson Steven , Park Chandler H. 
Published: June 2023

e23005 Background: Lower socioeconomic (SE) regions are often plagued extensively by healthcare outcome disparities. In searching for the root of this injustice, lack of access to the latest medical information has frequently been cited as a major contributor to these inequities. To address this, MedNews Week (MNW), a free, virtual education platform was developed to provide global health education through weekly oncology programming. The leading show, Keynote Conference, features live virtual presentations from oncology’s premier global leaders discussing the latest developments in the field. The aim of this study was to assess the global reach and impact of this platform for healthcare professionals (HCP). Methods: From September 2022 to January 2023, 37 MNW lectures on solid tumors and heme malignancies were showcased on VuMedi—a video platform providing free education content to HCP. Data collected from VuMedi included location, total page/video views, impressions, tumor subtype views and impressions, and occupation demographics. This information was analyzed to evaluate and assess the global reach of MNW on the VuMedi platform. Results: During this 5-month period, MNW experienced steady linear growth generating 5,643,257 page/video views with global viewership from 22 countries, including US, England, Canada, Brazil, and India (Table). Significant viewership was also observed from lower SE countries including Nigeria, Sudan, Georgia, and Bangladesh. Viewers were largely surgeons compared to Allied HCP (11:2). Higher viewership was observed for solid tumor presentations [706 (0.012%) page views and 9717 (7%) impressions] compared to heme malignancies [689 (0.001%) page views and 1688 (1.22%) impressions]. Within solid tumors, GI oncology keynotes were most viewed— generating 3755 (0.06%) page views and 28067 (20%) impressions, and the highest number of registrations recorded for this category. Conclusions: MNW continued growth in viewership and global reach amongst HCPs and demonstrates its emergence as a viable outlet to contribute to global oncology education, especially in lower SE areas. While previous studies have identified internet access and cost as barriers to high-quality medical information, MNW has experienced steady growth and reachability especially within these limited areas. The platform’s ability to showcase global leaders to HCP offers a practical approach to combat educational inequity and positively impact oncology education globally. [Table: see text]
Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
Authors: Khosla Atulya Aman , Ozair Ahmad , Subash Nishanth , Kumar Abhishek , Pereslete Alyssa , Mirza Sahaam , Bellur Shreyas S , Garje Rohan , Ahluwalia Manmeet Singh 
Published: June 2023

e23006 Background: Women and individuals from low- and lower-middle-income countries (LMICs) are under-represented in oncology literature, particularly in high-impact publications. LMIC clinicians face multipronged barriers to impactful research. Unlike practice guidelines of oncology societies like ASCO, authors worldwide can potentially contribute to genitourinary (GU) oncology-related Cochrane Reviews, a potentially representative sample of global evidence synthesis efforts in the field. However, the state of authorship diversity here is unknown, which this study sought to determine. Methods: We retrospectively searched the Cochrane Database, using the filter “Topic: Urology”, and extracted authorship data for all reviews related to genitourinary cancers, published until 25 July 2022. We divided authors’ national affiliation into either low- and lower-middle-income countries (LMICs) or non-LMICs based on World Bank 2022 classification. For reviews having collaboratives listed as group authors, we treated the collaborative belonging to one country as a single author, instead of analyzing all collaborators separately to prevent data skew from several included individuals. Given the higher accuracy of manual web-searches for ascertaining gender over algorithmic estimation, we utilized the former to achieve ≥90% ascertainment. We endeavored to capture at least one webpage that demonstrated their gender or pronouns, like institutional profile, and used historical gender conventions. Results: A total of 54 GU oncology-related reviews, co-authored by a total of 324 authors, were included. 53 reviews were published by the Cochrane Urology Group, while one review was published by the Cochrane Incontinence Group. Countries with the highest representation of co-authors were the US (24.1%), UK (25.3%), Germany (23.5%), South Korea (6.8%), Australia (6.2%), Netherlands (3.7%), China (2.8%), Canada (2.5%), Brazil (1.5%). No authors were from LMICs. Gender could be ascertained for 94.14% (N = 305/324) of co-authors. Women made up 27.5% (N = 84/305) of co-authors, 16.0% (N = 8/50) of first authors, and 16.89% (N = 9/53) of corresponding authors. Conclusions: Women authors are better-represented in Cochrane Reviews related to genitourinary cancers compared to urology-specific journals, while LMICs were noted to have no representation. Global capacity-building efforts are warranted for enhancing the involvement of LMIC urologists with evidence synthesis. Equitable authorship representation may help expand both the focus and the utilization of high-impact evidence synthesis literature.
Website and social media presence for National Cancer Institute Community Oncology Research Program (NCORP) sites.
Authors: Steinmetz Carsten Z , Roberts Katie , Kennedy Alaina , Foust Melyssa , Mertz-Rivera Kamara L. , Curtis Amarinthia E. 
Published: June 2023

e23009 Background: The National Cancer Institute Community Oncology Research program (NCORP) is a network which brings cancer clinical trials and care to patients within their own communities. Currently, NCORP consists of 46 sites throughout the United States which receive grant funding through the NCI. We aim to describe the scope of social media use and NCORP dedicated websites. We also aim to describe the correlation between media usage and funding. Methods: We searched NCORP websites and online search engines to identify the social media presence of different NCORP sites. Facebook, Instagram, LinkedIn, and Twitter were the social media sites chosen. Additionally, we searched for NCORP dedicated websites that were separate and distinct from the host institution. We were able to gather public data outlining the total funding received by each site in a three-year span (2019-2021) using the NIH RePORTER. Data was summarized using descriptive statistics. Results: A total of 15 out of 46 sites were determined to have a social media presence, 11 out of 46 sites had NCORP dedicated websites, and 7 out of 46 had both a social media presence and a dedicated website. The social media sites used for the NCORPs were as follows Facebook 8, Twitter 5, LinkedIn 3, and Instagram 1. The content information within the 11 dedicated websites were as follows clinical trials 9, newsletters 2, and provider information 8. All 11 websites had the NCI watermark badge (100% of NCORP websites). The average three-year funding for NCORP sites utilizing social media was $5,371,610. The average three-year funding for NCORP sites without social media was $4,230,552. The average three-year funding for NCORP sites utilizing dedicated websites was $4,681,708. The average three-year funding for NCORP sites without dedicated websites was 4,584,321. There was no statistical significance between funding and websites or social media accounts. Conclusions: NCORPs have an opportunity to disseminate high quality reliable information about cancer clinical trials that meet the need of patients and clinical care providers. However, NCORP sites are rarely a distinct voice on social media or with dedicated websites. Sites may not have resources for this type of communication or may promote the work of NCORP through the communication channels of the host institution(s). Sites with websites or social media accounts had higher average funding. However, this was not significant. Whether social media and NCORP dedicated websites contribute meaningfully to the work of NCI clinical trials remains to be seen and is beyond the scope of this investigation.
Effect of dual properties of regorafenib in osteosarcoma on tumor progression and bone parameters in mouse preclinical models.
Authors: Munoz Garcia Javier , Vargas-Franco Jorge William , Bompas Emmanuelle , Cochonneau Denis , Ollivier Emilie , Kerzerho Jerome , Brahmi Mehdi , Blay Jean-Yves , Heymann Maire-Francoise , Lezot Frederic , Heymann Dominique 
Published: June 2023

e23501 Background: Osteosarcoma (OS) constitutes the most frequent malignant primary bone tumor in children and young adults. Actual treatments in OS are based in a multimodal therapy that combines pre- and post-surgery polychemotherapies including cisplatin, doxorubicin, ifosfamide and/or methotrexate. Regardless the use of this polychemotherapeutic approach, the five years overall survival for patients has not improved during the last four decades and there is a clinical need to identify new active drugs in OS. An interesting strategy implies the use of compounds that showed therapeutic benefits in other solid tumors. Regorafenib, a small molecule with multi-target tyrosine kinase inhibitory activity against FGFR-1 and -2, KIT, PDGFR, RAF, RET, TIE2 and VEGFR-1, -2 and -3, showed an anti-angiogenic/oncogenic properties in various solid tumors that includes metastatic colorectal cancer, hepatocarcinoma and breast cancer. In addition, regorafenib also inhibits in vitro the proliferation of several pediatric solid tumor cell lines such as rhabdomyosarcoma, Ewing sarcoma and OS. Methods: The present work aims to decipher the in vitro and in vivo effects of regorafenib in OS preclinical models. Results: The treatment of MNNG-HOS, KHOS and 143B osteosarcoma cell lines with Regorafenib resulted in the inhibition of cell proliferation in a dose dependent manner. The gene expression profiles of MNNG-HOS and 143B cells treated or not with regorafenib and analyzed by NanoString technology revealed a specific regulation of molecular pathways by regorafenib in both cell lines. The in vivo effect of regorafenib was then analyzed in immunocompetent (mouse MOS-J cells inoculated in C57Bl/6 mice) and immunodeficient (human MNNG-HOS and 143B OS cells injected in Nude mice) murine osteosarcoma models. In all the cases, a significant reduction of primary tumor growth was observed as well as a significant decrease of lung metastases compared to untreated mice. Interestingly, the cortical and trabecular bone mineral density were significantly increased in regorafenib treated mice compared to untreated groups as demonstrated by X ray microtomodensitometry in all models. Conclusions: Our results support the use of regorafenib as an alternative treatment in metastatic OS and demonstrated for the first time the its bone protective effect.
The impact of demographic factors on patients with intraosseous well-differentiated osteosarcoma.
Authors: Cook Madison , Wu Xinxin , Keirns Darby , Silberstein Peter T. , Hsia Beau 
Published: June 2023

e23502 Background: Well-differentiated intraosseous osteosarcoma (WDIO) is a rare cancer that primarily affects the medullary cavity of the femur and tibia. While WDIO accounts for only 2% of osteosarcomas, 10% of patients do not survive past 5 years. Due to its rare nature, there is difficulty diagnosing WDIO, and as such, patients present in later stages of the disease with more secondary complications. There is no standard of treatment for WDIO. The socioeconomic factors of WDIO have yet to be addressed in literature using data from the NCDB. The purpose of this study is to analyze the demographic and socioeconomic factors of patients diagnosed with WDIO, using the National Cancer Database (NCDB) to better understand its epidemiology. Methods: The National Cancer Database (NCDB) was used to create a retrospective cohort analysis of histologically-confirmed WDIO patients (N = 30) from 2004 – 2020. Regression analysis was performed to interpret incidence trends and descriptive statistics on specific demographic factors (sex, race, age, insurance status, income, type of treatment, facility type, and Charleson-Deyco score) on patients with WDIO. Results: There were a total of 30 patients in the NCDB database identified with a diagnosis of WDIO. From 2004 – 2020, there has been an increasing incidence rate (R2 = 0.3). The mean age of WDIO diagnosis is 37.9 (SD = 18.6 range = 8 – 80 years). The long bones of the upper and lower limbs accounted for 63.4% of the primary sites of the cancer. More women (63.3%) than men were diagnosed. The majority (83.3%) of the patients had Charlson-Deyo comorbidity scores of 0. The upper income quartile contained the highest percentage of patients (42.3%) compared to each of the other lower quartiles. There were more privately insured patients (63.3%) than patients on Medicaid/Medicare. Over half of the patients (51.9%) came from metropolitan areas with a population greater than 1 million. More than half of the patients were treated at research/academic facilities (51.3%). The main form of treatment in patients with WDIO was radical excision with limb salvage (60%). Local and partial resection occurred in 30% of the cases. Conclusions: This study addresses a significant gap in knowledge on the diagnosis of WDIO and its relation to socio-demographic factors. The majority of the patients present with WDIO in the long bones of the upper and lower body, which is concurrent with previous reports of WDIO. From our analysis, patients with WDIO tend to be in the upper income quartile, live in densely-populated urban areas, and receive radical excision surgery in academic programs. This preliminary research on the impacts of demographic and socioeconomic factors on WDIO could bring more awareness to its diagnosis. Further research on the impacts of these demographics on treatment options and overall prognosis would significantly enhance our knowledge regarding the social inequality surrounding WDIO.
Clear cell chondrosarcoma: A national analysis exploring the demographic features.
Authors: Tade Yanick , Hsia Beau , Keirns Darby , Silberstein Peter T. , Wu Xinxin 
Published: June 2023

e23503 Background: Clear cell chondrosarcoma (CCCS) is an uncommon cancer and variant of chondrosarcoma affecting the proximal portion of long bones, commonly the femur or humerus. This low-grade and slowly progressing malignant tumor is often mistaken for benign tumors (i.e. chondroblastoma), but its histological features of benign giant cells and cells with clear cytoplasm alongside pathologic, roentgenographic, and clinical characteristics aid in its distinction. Accurate identification will guide the establishment of standard treatment algorithms and further improve treatment outcomes. CCCS has an overall 10-year survival rate of 89% with a median time to death from disease of 15.3 years. The National Cancer Database (NCDB) was analyzed to determine how patient demographic characteristics affect the diagnosis of CCCS. Methods: A retrospective cohort study from 2004 to 2020 was conducted using the NCDB. 188 patients were found with a histologically confirmed diagnosis of CCCS (ICD-9242-3). Gender, race, Hispanic origin, insurance coverage, type of treatment facility, and distance from patient residence to treatment facility were analyzed via descriptive statistics and trends in incidence were interpreted using regression analysis. Results: The frequency of patients diagnosed with CCCS has remained consistent since 2004 (R2 = 0.1) with over 11 diagnoses per year. Of the 188 patients found, the average age of diagnosis was 47.8 years (SD = 16.7, range = 14 – 90 years). Approximately two-thirds of patients were male (68.1%) and the remainder were female (31.9%). Most of the patients were White (84.6%). Patient Hispanic status could not be accurately determined due to limited data. More patients were in the top income quartile (31.9%) than those in the second (26.1%), third (19.7%), or fourth (12.2%) quartiles. The other 10.1% were of unknown income status. Most patients were privately insured (61.7%), followed by coverage under Medicare/Medicaid (27.1%). More patients lived in metropolitan counties with a population of 250,000 or more (85%) compared to less-populated urban or rural areas (15%). A large percentage of patients were treated at an academic/research program (61.6%) compared to non-academic programs (38.4%). Patients traveled an average of 65.8 miles (SD = 101.4, range = 0.8 – 793.0) to get to the treatment facility. Conclusions: CCCS remains a rare diagnosis. This study explores a significant gap in existing knowledge on patient characteristics that might present with CCCS. Most patients were White, insured by private insurance, in the top quartile of income earners, and lived in metropolitan areas. This novel study of socioeconomic factors in CCCS patients suggests that patients with higher socioeconomic status in highly-populated areas might have better access to this uncommon diagnosis. As such, additional research to comprehend the role that socioeconomic status might have on CCCS would be beneficial.